Recent studies have demonstrated that suppression of IGFBP2 expression mitigates FGF1-induced activation of AMPK, supporting a critical role for IGFBP2 in mediating the therapeutic effects of FGF1 on obesity-associated hepatic steatosis (26). Here, FGF1 is linked to fatty liver disease.